Location: Solmed Polyclinic (Zagreb)
Study Drug: Experimental drug is an immunoproteasome inhibitor that selectively acts on a wide range of autoimmune diseases.
Main Inclusion Criteria: Adult patients diagnosed with systemic lupus erythematosus (SLE) and signs of kidney damage (elevated blood creatinine or proteins in the urine), with protein concentration in 24-hour urine greater than 1 g/24h.
Status: Enrolling new patients
Start of patient enrollment: December 2023
End of patient enrollment: February 2025
